Analysts expect Tilray Inc (NASDAQ:TLRY) to post earnings per share (EPS) of ($0.19) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Tilray’s earnings, with estimates ranging from ($0.33) to ($0.09). The company is expected to issue its next quarterly earnings report on Tuesday, February 12th.
According to Zacks, analysts expect that Tilray will report full year earnings of ($0.63) per share for the current financial year, with EPS estimates ranging from ($0.79) to ($0.51). For the next financial year, analysts expect that the business will post earnings of ($0.55) per share, with EPS estimates ranging from ($1.40) to ($0.12). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Tilray.
Tilray (NASDAQ:TLRY) last posted its earnings results on Tuesday, November 13th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.08). The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $10.25 million. Tilray had a negative net margin of 121.22% and a negative return on equity of 60.74%. The business’s revenue for the quarter was up 85.2% on a year-over-year basis.
A number of hedge funds have recently modified their holdings of the business. Captrust Financial Advisors acquired a new position in Tilray in the 3rd quarter worth $103,000. IFP Advisors Inc acquired a new position in Tilray in the 3rd quarter worth $154,000. G&S Capital LLC acquired a new position in Tilray in the 3rd quarter worth $155,000. Independent Advisor Alliance acquired a new position in Tilray in the 3rd quarter worth $216,000. Finally, Raging Capital Management LLC acquired a new position in Tilray in the 3rd quarter worth $215,000. Hedge funds and other institutional investors own 6.08% of the company’s stock.
NASDAQ:TLRY opened at $96.00 on Friday. The company has a current ratio of 5.43, a quick ratio of 4.98 and a debt-to-equity ratio of 0.05. Tilray has a twelve month low of $20.10 and a twelve month high of $300.00.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Story: How is the S&P 500 index different from the DJIA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.